Sign inLondon summit highlights state of research into drug-based, cell and genetic hearing therapies
The RNID claims to be the only charity in the UK dedicated to funding biomedical hearing research, and on November 13 the group hosted the RNID Hearing Therapeutics Summit in Wimpole Street, London, an event sponsored by Shionogi, Acousia Therapeutics and Senorion, while Norgine provided a grant as funding but with no direct involvement in the event.
Carla Gollege And Professor Jane Sowden
Photo courtesy of RNID
Vital research into the next generation of treatments for hearing loss and tinnitus is on the point of breakthroughs that could dramatically change perspectives across many aspects of hearing health.
[caption id="attachment_141497" align="alignright" width="300"] RNID CEO, Harriet Oppenheimer at the Hearing Therapeutics Summit in London this November.[/caption]
As close to 120 people gathered at 1 Wimpole Street on November 13 for an all-day event reflecting the state of such research, Ralph Holme, Director of Research at the Royal National Institute for Deaf People - the body organising and hosting the event - spoke of laboratory progress being on the point of epoch-changing discoveries.
"For decades, treatments for hearing loss and tinnitus have been restricted to...
This content is only accessible to registered users of the website audiology worldnews
Already subscribed Log in
